Clinical Trial Update: Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating BCG followed by sunitinib for high-risk non-muscle invasive urothelial carcinoma of the bladder has completed, with results posted in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Urothelial Carcinoma of the Bladder
• Urinary Tract Urothelial Carcinoma

Drugs mentioned

• BCG (Bacillus Calmette-Guerin) (Bacillus Calmette-Guerin)
• Sunitinib (sunitinib)

Snippet

Sponsor: University of Michigan | Conditions: Urinary Tract Urothelial Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2019-09-23